Results 41 to 50 of about 2,602 (175)

Daclatasvir Plus Asunaprevir Dual Therapy for Chronic HCV Genotype 1b Infection: Results of Turkish Early Access Program

Annals of Hepatology, 2017
Background: Daclatasvir and asunaprevir dual therapy is approved for the treatment of HCV genotype 1b infection in several countries. Aim: To evaluate the efficacy and safety of daclatasvir and asunaprevir dual therapy in Turkish patients.
Seyfettin Köklü, Iftihar Köksal, Ulus Salih Akarca, Ayhan Balkan, Rahmet Güner, Aylin Demirezen, Memduh Sahin, Sila Akhan, Reşat Ozaras, Ramazan Idilman   +9 more
doaj   +1 more source

Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b. [PDF]

PLoS ONE, 2016
BACKGROUND:Decreased hemoglobin (Hb) level has been supposed to be a relatively rare side effect of a combination therapy against hepatitis C virus that consists of the NS5A inhibitor daclatasvir (DCV) and the NS3/4A protease inhibitor asunaprevir (ASV).
Nobuyuki Matsumoto, Hiroki Ikeda, Ryuta Shigefuku, Nobuhiro Hattori, Tsunamasa Watanabe, Kotaro Matsunaga, Tetsuya Hiraishi, Tomohiro Tamura, Yohei Noguchi, Yasunobu Fukuda, Toshiya Ishii, Chiaki Okuse, Akira Sato, Michihiro Suzuki, Fumio Itoh   +14 more
doaj   +1 more source

A hepatitis C-vírus-bázispolimorfizmus jelentősége a kezelésben [PDF]

, 2015
Absztrakt A krónikus C-vírus hepatitis kezelése az elmúlt huszonöt évben igen jelentős fejlődésen ment keresztül.
Tornai, István
core   +1 more source

The modern options of chronic hepatitis C antiviral therapy with daclatasvir: results of named patient program

Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2018
Introduction. The options of antiviral therapy (AVT) in the stages of severe liver fibrosis and cirrhosis (LC) as well as in the patients with comorbidities for the long time were limited to the standard therapy by pegilated interferon (peg-IFN) in ...
V. T. Ivashkin, M. V. Mayevskaya, D. T. Abdurakhmanov, I. G. Bakulin, N. I. Geyvandova, M. L. Zubkin, S. N. Kizhlo, A. V. Kuznetsova, I. B. Latysheva, N. A. Mamonova, V. G. Morozov, O. I. Sagalova, Ye. V. Esaulenko, Ye. O. Lyusina   +13 more
doaj   +1 more source

Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection. [PDF]

PLoS Computational Biology, 2015
Recent discoveries of direct acting antivirals against Hepatitis C virus (HCV) have raised hopes of effective treatment via combination therapies.
Ruian Ke, Claude Loverdo, Hangfei Qi, Ren Sun, James O Lloyd-Smith   +4 more
doaj   +1 more source

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices [PDF]

, 2014
SUMMARY. Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C virus (HCV) will become a reality in the near future. In replacing interferon-based therapies, all-oral regimens are expected to be more tolerable, more effective,
Afdhal, N H, Castera, L, Church, D R, Dee, L, Graham, C, Jacobson, I M for the New Paradigm of HCV Therapy Meeting Participants, Litwin, A H, Mehta, S H, Muir, A, Poynard, T, Razavi, H, Schooley, R T, Sulkowski, M S, Talal, A H, Thomas, D L, Ward, J W, Zeuzem, S   +16 more
core   +1 more source

Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response

Journal of the Formosan Medical Association, 2017
Daclatasvir is a nonstructural protein 5A inhibitor with potent activity against hepatitis C virus genotypes 1–6 in vitro, and asunaprevir is a nonstructural protein 3 protease inhibitor with activity against genotypes 1, 4, 5, and 6.
Chun-Ming Hong, Chun-Jen Liu, Shiou-Hwei Yeh, Pei-Jer Chen   +3 more
doaj   +1 more source

Recent advances in managing chronic HCV infection: Focus on therapy in patients with severe liver disease [PDF]

, 2016
Chronic hepatitis C virus (HCV) infection still represents a major public health problem, as it is thought to be responsible for more than 350,000 deaths around the globe on a yearly basis.
Maan, R. (Raoel), Meer, A.J.P. (Adriaan) van der   +1 more
core   +5 more sources

Evaluating Andrographolide as a Potent Inhibitor of NS3-4A Protease and Its Drug-Resistant Mutants Using In Silico Approaches

Advances in Virology, 2015
Current combination therapy of PEG-INF and ribavirin against the Hepatitis C Virus (HCV) genotype-1 infections is ineffective in maintaining sustained viral response in 50% of the infection cases.
Vivek Chandramohan, Anubhav Kaphle, Mamatha Chekuri, Sindhu Gangarudraiah, Gowrishankar Bychapur Siddaiah   +4 more
doaj   +1 more source

Pharmacophore anchor models of flaviviral NS3 proteases lead to drug repurposing for DENV infection

BMC Bioinformatics, 2017
Background Viruses of the flaviviridae family are responsible for some of the major infectious viral diseases around the world and there is an urgent need for drug development for these diseases.
Nikhil Pathak, Mei-Ling Lai, Wen-Yu Chen, Betty-Wu Hsieh, Guann-Yi Yu, Jinn-Moon Yang   +5 more
doaj   +1 more source